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This study explored whether longer provider delays (between first presentation and treatment) were associated with later stage and poorer survival in women with symptomatic breast cancer.

Methods
Data from 850 women with symptomatic breast cancer were linked with the Scottish Cancer Registry; Death Registry; and hospital discharge dataset. Logistic regression and Cox survival analyses with restricted cubic splines explored relationships between provider delays, stage and survival, with sequential adjustment for patient and tumour factors.

Results
Although confidence intervals were wide in both adjusted analyses, those with the shortest provider delays had more advanced breast cancer at diagnosis. Beyond approximately 20 weeks, the trend suggests longer delays are associated with more advanced stage, but is not statistically significant. Those with symptomatic breast cancer and the shortest presentation to treatment time (within 4 weeks) had the poorest survival. Longer time to treatment was not significantly associated with worsening mortality.

Conclusions
Poor prognosis patients with breast cancer are being triaged for rapid treatment with limited effect on outcome. Prolonged time to treatment does not appear to be strongly associated with poorer outcomes for patients with breast cancer, but the power of this study to assess the effect of very long delays (>25 weeks) was limited.  Efforts to reduce waiting times are important from a quality of life perspective, but tumour biology may often be a more important determinant of stage at diagnosis and survival outcome.

Highlights
	We explored if longer provider delays impact stage and mortality in breast cancer
	We used a large dataset linking medical records to high quality national registers
	We utilised innovative statistical advances and consider  the non-linear effect of diagnostic delay on advanced stage and mortality.
	We found no evidence that even moderate provider delays were associated with more advanced stage breast cancer
	We found no evidence that even moderate provider delays were associated with higher breast cancer mortality
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INTRODUCTION
An influential systematic review concluded in 1999 that longer total diagnostic delays resulted in poorer survival for women with symptomatic breast cancer.[1] The review was not directly informative on provider delay (i.e. between presentation to health services and treatment) but has profoundly influenced the belief that reducing provider delay is critical to improving cancer outcomes.[2,3,4]

Despite this, there remains no convincing evidence that longer provider delays lead to poorer breast cancer outcomes, although previous research has had limitations.[5] In particular most analyses include delay as a categorical non-continuous variable, and introduce bias by adjusting for intermediate factors, such as tumour stage.[5] When such limitations were addressed by a Danish group, the relationship between provider delay and colorectal cancer mortality was described by a u-shaped curve, incorporating the waiting time paradox (i.e. those with aggressive poor prognosis tumours present and are treated earliest) but also evidence of poorer outcomes once provider delay exceeded six weeks.[5] However, they did not control for several important potential confounders, including markers of tumour biology (e.g. tumour grade, morphology, oestrogen receptor status). When we adopted their methods in a sample of colorectal cancer patients diagnosed in Northeast Scotland between 1997 and 1998, but adjusted for symptoms and tumour biology, we found no evidence of later stage or lower survival with longer provider delays. We concluded that tumour biology may be more important than provider delay in determining outcome.[6] For breast cancer, there is a long-standing recognition that tumour biology could be more important than delays in determining outcome.[7]





Data were linked from four datasets. The CRUX (Comparing Rural and Urban Cancer Care) dataset, collected in 2000 and 2001, provides primary care data on women diagnosed in Northern Scotland with symptomatic breast cancer between 1997 and 1998.[8] Data includes details of consultations with relevant symptoms and signs before diagnosis.[8,9] Date of first presentation in primary care was the first record of a relevant sign or symptom of breast cancer preceding diagnosis. Subsequently dates of first hospital referral, diagnosis, and first treatment were recorded. Patients with symptoms and signs more than two years before treatment were excluded. These data were linked to the Scottish Cancer Registry (SCR) for information on stage at diagnosis and other tumour variables (grade, morphology, oestrogen receptor status)[10,11]. Further linkage was to the General Register Office for Scotland Death Registry (for date of death, primary and secondary causes), and SMR01, an episode-based record of all discharges from Scottish hospitals, which was used to calculate Charlson co-morbidity indexes [12,13,14]. The SCR and CRUX datasets were linked directly using the SCR ID number. The SMR01 and death records were linked using computerised probability linkage[15]. Linkage was performed at ISD Scotland, the final dataset supplied as an SPSS data file with all personal identifying information removed.

Statistical analysis
Data were analysed using Stata (StataCorp, Version 11, Texas, USA).  A stringent p-value of ≤0.01 was used to denote statistical significance throughout, chosen to minimise Type 1 errors from multiple testing.   


The main predictor variable was time from first presentation in primary care to first treatment or to definitive diagnosis as recorded in the SCR if no treatment was given.  The two main outcomes were stage at diagnosis (I- IV) and all-cause survival from date of first presentation in primary care. Survival was measured from date of presentation rather than date of diagnosis or treatment to overcome lead-time bias occurring when patients diagnosed soon after presentation inevitably have longer survival measured from date of diagnosis than those experiencing delays before diagnosis, even if delays had no impact on time of death. This could result in an unjustified conclusion that short provider delays were associated with longer survival and vice-versa. However, using date of presentation to calculate survival could inadvertently introduce another bias because the exposure (long provider delay) is, to some extent, inherently associated with the outcome (survival time). This could result in concluding that long provider delays were associated with longer survival and vice-versa. Sensitivity analysis was therefore conducted to explore this, where survival from date of first treatment (or from diagnosis if no treatment was given) was used as the outcome.  

Other variables considered for inclusion in one or more models were: age and Charlson co-morbidity score (both analysed as continuous variables), smoking status, Carstairs deprivation quintile[16], tumour grade and morphology, oestrogen receptor status, treatment received (surgery, chemotherapy, radiotherapy, hormonal therapy), place of presentation and speciality referred to. Tumour stage, as a predictor variable was excluded from the multivariate survival models since, if time between presentation and treatment is an important factor for survival, then its effect would be via more advanced disease stage.

Logistic regression was used to calculate unadjusted odds ratios (with 99% CI) of provider delay for disease stages III/IV compared to stages I/II.  This was followed by two sequentially adjusted models including potential confounders that were deemed to be clinically important and/or showed a univariate relationship with outcome at a conservative p≤0.10.  In model 2, age, smoking status, Carstairs deprivation quintile, Charlson index, place of presentation and speciality clinic were included. Model 3 included the addition of tumour grade, morphological type of tumour, and oestrogen receptor status. Treatment variables, clinical signs of disease, tumour size and nodal status were not included in the multivariate model since these will be correlated with stage.

The chi-squared test for trend was used to examine the linear relationship between stage and each of Carstairs deprivation quintile and smoking status.    

To model the non-linear relationship between provider delay and stage, a restricted cubic spline (RCS) procedure was adopted [17]. This uses multiple polynomial line segments within the range of provider delay, the boundaries of these line segments being called knots. Four knots were placed at equally spaced centiles of the distribution of provider delay. A spline function was assumed to be significant if the p-value for the model chi-square was <0.01 and the association is assumed to be non-linear if the spline coefficients differ significantly from each other based on the Wald test for linearity. A provider delay value of 4 weeks was used as the reference value to estimate odds of late stage disease in the logistic RCS analyses and the hazard ratio of mortality in the RCS Cox analyses. As before, an unadjusted model and two further adjusted models were run.   

Cox survival analysis was employed to examine the relationship between provider delay and mortality with unadjusted hazard ratios (HRs) and 99% CIs being calculated. Three sequential models were subsequently fitted.  The first adjusted for age, smoking status, Carstairs deprivation quintile, place of presentation, speciality clinic and Charlson index.  The second further adjusted for tumour grade, morphological type of tumour, and oestrogen receptor status and the final model further included surgery received, chemotherapy, radiation therapy and hormone therapy.  The proportional hazard assumption is based on Schoenfeld residuals and no violations were detected in the current analyses.[18]

RESULTS
A total of 850 women with symptomatic breast cancer were included in the survival analysis. 777 had data on stage (Table 1). The median (IQR) provider delay was 7 (5-10) weeks. The median (IQR) age was 63 (49-75) years and 27.3% of the women were in the least deprived quintile with 7% in the most deprived quintile.

Stage as the outcome
Table 1 shows the univariate analysis of factors associated with more advanced stage at diagnosis of symptomatic breast cancer. Less time between presentation and treatment was not a linear predictor of more advanced breast cancer at diagnosis when time was measured as a continuous factor in either days or weeks.  Older age was associated with more advanced stage at presentation.  The percentage of women with advanced stage by age group was <50 (16.7%), 50-64 (20.4%), 65-74 (26.8%), 75-84 (23.5%) and 85+years (52.6%).  .There was a significant linear trend of more advanced stage with increasing deprivation (p=0.007) but not with smoking status (p=0.719). Patients with higher grade tumours, those with poor morphological prognosis, and those with negative oestrogen receptor status were more likely to present at advanced stage. 

Table 2 shows the multivariate models used to determine factors predictive of presentation with more advanced disease. Following full adjustment, significant predictors of more advanced breast cancer at diagnosis were older age and higher grade tumours.  Provider delay as a spline function was significantly associated with stage in the unadjusted model (p<0.001) and the p-value for the non-linear association was p<0.001. The relationship between provider delay and stage of breast cancer at diagnosis is illustrated in Figures 1 and 2. Figure 1 displays spline curves for three sequential models, beginning with an unadjusted model. These curves plot the length of the provider delay on the X axis against the odds ratio of patients having more advanced stage disease on the Y axis. When the line dips below 1 it indicates that patients with this duration of provider delay are less likely to have advanced disease (stage III, IV). Adjustment for potential confounders has little impact on the spline curve.  Figure 2 shows the spline curve for the fully adjusted model with shaded 99% confidence interval. Although confidence intervals are wide, those with the shortest provider delays had the most advanced breast cancer at diagnosis. Prolonged provider delays did not appear to be significantly associated with more advanced stage breast cancer at diagnosis.

Supplementary table 1 shows the numbers in each of the diagnostic delay categories, the proportion having late stage and the descriptive summaries of the prognostic factors. Although the odds ratio for advanced disease is 4.71 among patients experiencing delays ≥ 39 weeks, this calculation was based on only nine patients and the 99% confidence intervals are wide and overlap 1.00.

Mortality as the outcome
Table 3 comprises the results of the univariate analysis of factors associated with mortality from breast cancer. On univariate analysis, a longer time to treatment (weeks) was associated with better survival (HR 0.97, 99% CI 0.95-0.99). The percentage of women who died by age group was <50 (36.8%), 50-64 (44.0%), 65-74 (70.1%), 75-84 (87.8%) and 85+years (100%).  More advanced stage at diagnosis, older age, unknown smoking status and Charlson index were significantly associated with higher mortality for symptomatic breast cancer as was increasing deprivation (p<0.001 for linear trend) but not smoking status (p=0.741). Higher grade tumours, tumours with poor or unknown morphological prognosis, and those with negative or unknown oestrogen receptor status were all associated with increased mortality.  Tumours presenting at a home visit and those picked up at a non-surgical speciality clinic showed an association with increased mortality.  Regarding treatment factors, having received surgery or chemotherapy were all associated with reduced mortality.      

Table 4 shows the results of Cox regression models used to determine factors predictive of mortality from breast cancer before and after adjustment for potential confounders. In the unadjusted model, provider delay as a spline function was inversely associated with mortality (p<0.001) and the association was non-linear (p<0.001). Following full adjustment, older age, Carstairs quintile 4, Charlson index, chemotherapy and radiotherapy were all associated with higher hazards of mortality, whilst having received surgery or hormone therapy were associated with reduced mortality. 





Supplementary figure 1 show the fully adjusted spline curve for mortality when survival was estimated from the date of first treatment (or diagnosis if no treatment was undertaken) as opposed to the date of presentation. Using the start of treatment (or diagnosis) as the ‘anniversary date’ for survival analysis resulted in slightly increased hazard ratios, although this increased risk of death was not statistically significant. The ‘true’ effect of delays on mortality outcome may lie somewhere between the spline curves of Figures 3 and that of supplementary figure 1.

Supplementary table 1 includes the numbers in each of the diagnostic delay categories and the associated odds ratio (99% CI) of mortality. Once again, this suggests that the highest risk of death is seen in patients with the shortest delay (1-3 weeks, OR 1.77 (99% CI 1.37, 2.30)  , although the power to detect an effect of delays exceeding 25 weeks is limited by small numbers experiencing delays of this magnitude (odds ratio 0.88 (99% CI 0.28, 2.81).

DISCUSSION
Summary of Main Findings
Women with symptomatic breast cancer with a very short delay between presentation and treatment have a poor prognosis. This is consistent with prioritizing treatment for those with striking symptoms, and advanced disease, and less scope to influence outcome. In contrast, longer delays (beyond 4-5 weeks) do not appear to be associated with more advanced stage and lower survival once adjustments are made for symptoms and tumour factors. Future research on breast cancer delays should consider the impact of tumour biology as thoroughly and consistently as possible.

Strengths and Limitations
Some limitations must be acknowledged. This is an historical sample comprising women diagnosed with symptomatic breast cancer between 1997 and 1998. This predates management advances in breast cancer therapy, particularly widespread use of monoclonal antibodies. Such advances, however, may even further attenuate the relationship between provider delay and outcomes. However, the dated nature of the data is also an advantage since lengthy delays were less unusual 15 years ago, before government attention was really focused on waiting times. It might be more difficult to examine this issue using contemporary data, when long delays have become much less common.  The study was observational and retrospective, dependent on the quality of routinely collected data and data within medical records. Some data, e.g. tumour stage, were not available for all cases. However, this was a population-based sample including all women diagnosed within the study period, and did not limit the analyses to those treated within tertiary cancer centres only. In comparison to other studies it used a large sample, effective linkage to high quality routine datasets with relatively complete follow-up. Even so, the study may have been underpowered to detect a small effect of prolonged provider delay on breast cancer stage and survival outcome.  In particular, it is worth noting that a relatively small number of women (n=31, 3.6%) in the sample had markedly prolonged provider delays (i.e. beyond 25 weeks), constraining the ability to detect an effect of very long provider delay. On the other hand, delays of this magnitude probably represent systems failure on some level and are unlikely to ever be viewed as acceptable by the public and professionals. The study does not examine the effect of total delay on stage at diagnosis and survival since the first point of contact is GP referral.  This point has been discussed by others.[19] It is very difficult to obtain reliable data on the exact date of first symptom(s) presentation.  This date may be very precise for alarm symptoms, but difficult to establish for more vague symptoms.      

Context with other Literature
Research since 1999 does not support a strong relationship between provider delay and poorer outcomes in symptomatic breast cancer, but most research has treated delay as a continuous variable and has been inconsistent in accounting for tumour biology. A Turkish study concluded that longer provider delays had no effect on outcome, with a small US study finding that provider delays as long as 36 months did not worsen outcome.[20,21] Another US study, not adjusting for tumour biology, found longer provider delays for poorer women but equivalent survival.[22] Conversely, a larger Scottish study found that delays longer than 240 days made conservative surgery less likely, but did not address tumour biology.[23] In two further US studies, neither adjusting for tumour grade, poorer survival for African American women could not be attributed to longer delays.[24,25]   As discussed by Maguire et al (1994), failure of studies to consider a non-linear effect of diagnostic delay on outcome may explain their inconclusive findings or findings of a reverse effect of long delays being associated with lower mortality.[26]  Maguire et al therefore recommended the use of cubic spline regression to allow for a flexible relationship between delay and outcome. This innovative approach has since been used by a Danish group and by ourselves in our published colorectal cancer paper.[5,6,19] 

Conclusion and Implications
Despite a study population comprising 850 women, we have not been able to demonstrate a statistically significant effect of even moderate provider delay on survival from breast cancer. While cancer waiting times targets can be justified on the grounds that delays affect patients’ psychological well-being, [27] it is important that they do not result in unjustified anxiety by reinforcing public perceptions that delays of any magnitude have a detrimental impact on survival prospects. Research must continue to discover the true effect of provider delays on breast cancer outcomes. As we have attempted to do, future research must incorporate methodological advances, such as analysing delay as a continuous variable and examination of its potential non-linear relationship with adverse outcomes.  Researchers must also adopt a thorough and consistent approach to key confounding factors, particularly the biological characteristics of breast tumours.
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Table 1: Univariate analysis showing the relationship between stage at diagnosis and various factors for women with symptomatic breast cancer


Factor		Total(n=777)	Stage I or II(n=593)	Stage III or IV(n=184 )	OR (99% CI)
					
					
Age (years)		63 (49, 75)	60 (49, 74)	69 (53, 79)	1.03 (1.01, 1.04)
Smoking status	Never smokerCurrentEx-smokerUnknown	303 (39.0)162 (20.9)101 (13.0)211 (27.2)	238 (40.1)126 (21.3)78 (13.2)151 (25.5)	65 (35.3)36 (19.6)23 (12.5)60 (32.6)	1.001.05 (0.57, 1.92)1.08 (0.53, 2.20)1.45 (0.85, 2.48)
Carstairs deprivation quintile	1  (least)2345 (most)	208 (27.3)210 (27.6)175 (23.0)115 (15.1)53 (7.0)	171 (29.5)160 (27.6)132 (22.8)80 (13.8)37 (6.4)	37 (20.4)50 (27.6)43 (23.8)35 (19.3)16 (8.8)	1.001.44 (0.77, 2.70)1.51 (0.79, 2.88)2.02 (1.00, 4.07)2.00 (0.81, 4.92)
Charlson index		0 (0, 0)	0 (0, 0)	0 (0, 1)	1.13 (0.99, 1.30)
Place of presentation	GP surgeryGP home visitOther/unknown	668 (86.0)43 (5.5)66 (8.5)	514 (86.7)31 (5.2)48 (8.1)	154 (83.7)12 (6.5)18 (9.8)	1.001.29 (0.52, 3.20)1.25 (0.59, 2.65)
Speciality clinic	Breast cancerGeneralOther medicalUnknown	492 (63.3)257 (33.1)19 (2.5)9 (1.2)	373 (62.9)205 (34.6)8 (1.4)7 (1.2)	119 (64.7)52 (28.3)11 (6.0)2 (1.1)	1.000.80 (0.49, 1.29)4.31 (1.26, 14.70)0.90 (0.11, 7.19)
Grade	Grade IGrade IIGrade III/IVUngradeable	99 (12.9)266 (34.6)265 (34.5)138 (18.0)	89 (15.2)221 (37.7)189 (32.2)88 (15.0)	10 (5.5)45 (24.9)76 (42.0)50 (27.6)	1.001.81 (0.70,4.72)3.58 (1.42, 9.05)5.06 (1.91, 13.38)
Morphological prognosis	Very good/goodIntermediatePoor Other/unknown	127 (16.3)571 (73.5)59 (7.6)20 (2.6)	99 (16.7)448 (75.6)35 (5.9)11 (1.9)	28 (15.2)123 (66.9)24 (13.0)9 (4.9)	1.000.97 (0.53, 1.79)2.42 (1.01, 5.83)2.89 (0.80, 10.43)
Oestrogen receptor status	NegativePositiveUnknown	204 (26.3)416 (53.5)157 (20.2)	139 (23.4)345 (58.2)109 (18.4)	65 (35.3)71 (38.6)48 (26.1)	1.000.44 (0.26, 0.73)0.94 (0.52, 1.70)
Values are n (%) or median (IQR)
OR = odds ratio of stage III/IV vs I/II




Table 2: Logistic regression model with a 4 knot restricted cubic spline for the association of time from 1st presentation on stage of breast cancer (4 week delay as reference group)

		Model 1	Model 2	Model 3
		OR (99% CI)	OR (99% CI)	OR (99% CI)
Time from 1st presentation (weeks)	4	1.00	1.00	1.00
	13	0.48 (0.30, 0.77)	0.45 (0.27, 0.75)	0.49 (0.29, 0.85) 
	26	0.50 (0.24, 1.02)	0.48 (0.22, 1.05)	0.53 (0.23, 1.21)
	39	1.02 (0.45, 2.29)	0.96 (0.40, 2.33)	0.97 (0.38, 2.47)
Age (years)			1.02 (1.00, 1.04)	1.03 (1.01, 1.05)
Smoking status	Non-smoker	1.00	1.00	1.00
	Current smoker		1.21 (0.62, 2.34)	1.16 (0.58, 2.33)
	Ex-smoker		1.10 (0.52, 2.32)	1.04 (0.48, 2.26)
	Unknown		1.39 (0.78, 2.48)	1.31 (0.72, 2.37)
Carstairs deprivation quintile	1 (least)	1.00	1.00	1.00
	2		1.41 (0.73, 2.73)	1.25 (0.63, 2.47)
	3		1.47 (0.74, 2.92)	1.19 (0.58, 2.44)
	4		2.01 (0.94, 4.30)	1.94 (0.88, 4.30)
	5 (most)		1.98 (0.77, 5.10)	1.93 (0.73, 5.11)
Charlson index			1.06 (0.90, 1.26)	1.04 (0.88, 1.24)
Place of presentation	GP surgery	1.00	1.00	1.00
	GP home visit		0.60 (0.22, 1.67)	0.48 (0.16, 1.42)
	Other/unknown		0.53 (0.19, 1.48)	0.52 (0.18, 1.50)
Speciality clinic	Breast	1.00	1.00	1.00
	General		0.61 (0.36, 1.05)	0.61 (0.35, 1.08)
	Other medical		2.68 (0.61, 11.87)	2.36 (0.52, 10.73)
	Unknown		0.72 (0.07, 7.52)	0.79 (0.07, 9.25)
Tumour grade	Grade I	1.00	1.00	1.00
	Grade II			1.66 (0.60, 4.60)









Model 1: Unadjusted 
Model 2: Model 1 further adjusted for age, smoking status, Carstairs deprivation quintile, Charlson index, place of presentation and speciality clinic
Model 3: Model 2 further adjusted for tumour grade, morphological prognosis and oestrogen receptor status  
OR = odds ratio of stage III/IV vs I/II





Table 3: Univariate analysis showing the relationship between patient and tumour factors, symptoms and signs with mortality for women with symptomatic breast cancer
Factor		Total n(n=850)	Died n(n=519)	Died (%)	HR	99% CI
						
						
Age (years)*		64 (50, 76)	72 (57, 79)		1.05	1.04, 1.06
Smoking status	Never smokerCurrentEx-smokerUnknown	322174109245	1839473169	56.854.067.069.0	1.000.971.211.41	0.70, 1.340.85, 1.741.07, 1.86
Carstairs deprivation quintile	1 (least)2345 (most)	22023619412459	1081451358638	49.161.469.669.464.4	1.001.421.821.881.61	1.02, 1.961.30, 2.541.29, 2.730.99, 2.61
Charlson index*		0 (0, 0)	0 (0, 1)		1.23	1.15, 1.30
Stage	I, IIIII, IVUnstaged	59318473	31614756	53.379.976.7	1.002.482.26	1.91, 3.211.55, 3.28
Grade 	Grade IGrade IIGrade III/IVUngradeable	108275284172	44154170145	40.756.059.984.3	1.001.551.884.27	1.00, 2.401.22, 2.912.74, 6.67
Place of presentation	GP surgeryGP home visitOther/unknown	7135780	4015563	56.296.578.8	1.005.132.26	3.51, 7.511.59, 3.20
Speciality clinic 	BreastGeneral surgeonOther medicalUnknown	5142932716	2911932510	56.665.992.662.5	1.001.274.571.59	1.00, 1.612.66, 7.830.69, 3.64
Morphological prognosis	Very good/goodIntermediatePoor Other/unknown	1356098026	743467425	54.856.892.596.2	1.001.083.544.71	0.77, 1.502.32, 5.432.59, 8.56
Oestrogen receptor status 	NegativePositiveUnknown	215442193	130241148	60.554.576.7	1.000.751.57	0.57, 0.991.15, 2.15




*Values are median (IQR)  HR hazard ratio   CI confidence interval


Table 4: Cox model to determine the association between time to 1st presentation and mortality (4 week delay as reference group)
----------------------------------------------------------------------------------------
                    Model 1           Model 2           Model 3           Model 4            
                   HR [99% CI]       HR [99% CI]       HR [99% CI]       HR [99% CI]
----------------------------------------------------------------------------------------
Time to 1st presentation (weeks)
13                 0.66 [0.52 0.84] 0.73 [0.57 0.94]  0.90 [0.70 1.18]  0.96 [0.73 1.26]
26                 0.63 [0.44 0.91] 0.78 [0.54 1.14]  1.03 [0.69 1.51]  1.11 [0.75 1.64]
39                 0.56 [0.34 0.94] 0.80 [0.47 1.36]  0.96 [0.56 1.63]  1.04 [0.60 1.78]

Age (years)                         1.04 [1.03 1.05]  1.04 [1.03 1.05]  1.05 [1.04 1.06]

Smoking status
Non-smoker                          1.00              1.00              1.00  
Current smoker                      1.22 [0.86 1.72]  1.16 [0.82 1.65]  1.26 [0.89 1.79]
Ex-smoker                           1.23 [0.85 1.77]  1.12 [0.77 1.63]  1.22 [0.84 1.78]
Unknown                             1.06 [0.79 1.42]  1.02 [0.76 1.37]  1.02 [0.76 1.37]

Carstairs deprivation quintile 
1 (least)                           1.00              1.00              1.00  
2                                   1.21 [0.87 1.69]  1.12 [0.80 1.57]  1.14 [0.81 1.60]
3                                   1.42 [1.01 2.01]  1.27 [0.89 1.80]  1.30 [0.91 1.85]
4                                   1.57 [1.06 2.32]  1.65 [1.11 2.45]  1.77 [1.19 2.63]
5 (most)                            1.24 [0.75 2.03]  1.19 [0.72 1.96]  1.18 [0.71 1.96]

Charlson index                      1.12 [1.04 1.20]  1.10 [1.02 1.19]  1.12 [1.03 1.21]

Place of presentation
GP surgery                          1.00              1.00              1.00  
GP home visit                       2.40 [1.58 3.64]  2.02 [1.29 3.17]  1.44 [0.90 2.31]
Other/unknown                       1.41 [0.92 2.16]  1.35 [0.88 2.07]  1.22 [0.79 1.90]

Speciality clinic
Breast                              1.00              1.00              1.00  
General surgeon                     1.10 [0.85 1.43]  1.16 [0.88 1.51]  1.18 [0.90 1.56]
Other                               2.23 [1.18 4.21]  2.10 [1.12 3.93]  1.45 [0.75 2.83]
Unknown                             0.80 [0.34 1.92]  0.72 [0.29 1.80]  1.01 [0.39 2.57]

Grade
Grade I                                               1.00              1.00  
Grade II                                              1.53 [0.97 2.40]  1.43 [0.91 2.25]
Grade III/IV                                          1.75 [1.09 2.80]  1.46 [0.91 2.36]
Ungradeable                                           1.98 [1.19 3.30]  1.56 [0.92 2.63]

Morphological prognosis
Very good/good                                        1.00              1.00  
Intermediate                                          1.19 [0.83 1.70]  1.10 [0.77 1.58]
Poor                                                  1.66 [1.01 2.72]  1.02 [0.60 1.73]
Other/unknown                                         1.87 [0.95 3.68]  1.44 [0.72 2.87]

Oestrogen receptor status
Negative                                              1.00              1.00  
Positive                                              0.76 [0.56 1.04]  0.83 [0.59 1.17]
Unknown                                               0.87 [0.59 1.27]  0.74 [0.49 1.12]

Surgery received  
No/unknown                                                              1.00  
Yes                                                                     0.33 [0.22 0.50]
Planned                                                                 1.42 [0.10 20.82]

Chemotherapy  
No/unknown                                                              1.00  
Yes                                                                     1.44 [1.04 1.99]

Radiation therapy
No/unknown                                                              1.00  
Yes                                                                     1.42 [1.10 1.85]
Planned                                                                 3.79 [0.95 15.13]

Hormone therapy
No/unknown                                                              1.00  
Yes                                                                     0.53 [0.36 0.77]
HR hazard ratio   CI confidence interval 
Model 1: Unadjusted 
Model 2: Model 1 further adjusted for age, smoking status, Carstairs deprivation quintile, place of presentation, speciality clinic and Charlson index
Model 3: Model 2 further adjusted for tumour grade, morphological prognosis and oestrogen receptor status















Model 1 (solid line): Unadjusted 
Model 2 (long dash dot):  Model 1 further adjusted for age, smoking status, Carstairs deprivation quintile, Charlson index, place of presentation and speciality clinic
































Model 1 (solid line): Unadjusted 
Model 2 (dot): Adjusted for  patient age, smoking status, Carstairs deprivation quintile, place of presentation , speciality clinic and Charlson index
Model 3 (short dash dot): Further adjusted for tumour grade, morphological prognosis and oestrogen receptor status
Model 4 (long dash): Further adjusted for  surgery received, chemotherapy,  radiation therapy and hormone therapy


















* adjusted for patient age, smoking status, Carstairs deprivation quintile, place of presentation , speciality clinic, Charlson index, tumour grade, morphological prognosis, oestrogen receptor status, surgery received, chemotherapy,  radiation therapy and hormone therapy





Supplementary Table 1: The relationship between stage at diagnosis, mortality, and other prognostic factors with provider delay for women with symptomatic breast cancer
							Diagnostic delay (weeks)
		1-3(n=165)	4-12(n=515)	13-25(n=69)	26-38(n=19)	39+(n=9)
Stage  3,4		54   32.7	108    21.0	14   20.3	3   15.8	5    55.5
 OR (99% CI) for stage 3,4 versus 1,2		1.83(1.10, 3.05)	1.00	0.96(0.42, 2.18)	0.71(0.14, 3.66)	4.71(0.82, 27.11)
Mortality		145   76.3	315    57.6	44    53.7	10   47.6	5    50.0
 OR (99% CI) for mortality		1.77(1.37, 2.30)	1.00	0.96(0.64, 1.46)	0.81(0.34, 1.85)	0.88(0.28, 2.81)
Age (years)		68.0 (51, 78)	63 (49, 75)	56.0 (48, 70)	54.0 (45, 73)	51.0 (47, 72)
Smoking status	Never smokerCurrentEx-smokerUnknown	69   41.826   15.814   8.556  33.9	201  39.0117  22.768   13.2129   25.1	21   30.416   23.2.13  18.819  27.5	8  42.12  10.54  21.15  26.3	4  44.41  11.12  22.22  22.2
Carstairs deprivation quintile	1  (least)2345 (most)	52  31.949  30.128  17.221  12.913 8.0	137  27.1131  25.9126  24.978   15.434    6.7	12  18.223  34.915  22.711  16.75  7.6	6  33.35  27.81   5.65  27.81  5.6	1   12.52   25.05   62.5--
Charlson index		0 (0, 2)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Place of presentation	GP surgeryGP home visitOther/unknown	129  78.211 6.725  15.2	460  89.328  5.427  5.2	54  78.33   4.412  17.4	16  84.21  5.3         2 10.5	9  100.0--
Speciality clinic	Breast cancerGeneralOther medicalUnknown	67 40.684  50.911  6.73  1.8	365  70.9143  27.8     5   1.0     2     0.4	38  55.125  36.33   4.43   4.4	15  79.04   21.1--	7   77.81   11.1-1  11.1
Grade	Grade IGrade IIGrade III/IVUngradeable	9.148   29.160  36.442  25.5	66   13.0191  37.6169  33.382   16.1	15   21.720  29.025  36.2       9  13.0	3   17.74  23.56  35.34  23.5	-3   33.35   55.61  11.1
Morphological prognosis	Very good/goodIntermediatePoor Other/unknown	31   18.8116   70.311    6.77  4.2	83  16.2383  74.437   7.212  2.3	8  11.653  76.88    11.6-	3   15.815   79.01   5.3-	2  22.24  44.42  20.01  11.1
Oestrogen receptor status	NegativePositiveUnknown	46  27.980  48.539  23.6	130  25.2280  54.4105  20.4	21  30.438  55.110  14.5	4 21.114  73.71  5.3	3  33.34  44.42  22.2




Supplementary Figure 1:: Spline curve of Cox proportional hazards model of provider delay (Time to treatment-weeks) on hazard ratio (shaded area are 99% CI) for mortality for symptomatic breast cancer cases after multi-adjustment for potential confounders (4 week delay as reference group)


* adjusted for patient age, smoking status, Carstairs deprivation quintile, place of presentation , speciality clinic, Charlson index, tumour grade, morphological prognosis, oestrogen receptor status, surgery received, chemotherapy,  radiation therapy and hormone therapy

Survival time is measured from date of first treatment (or diagnosis if no treatment given).  
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